Skip to main content

Table 6 Serum indicators of muscle damage during the WB-EMS intervention period

From: Effects of whole-body electromyostimulation combined with individualized nutritional support on body composition in patients with advanced cancer: a controlled pilot trial

Parameter

Study week

p-valueb

Baseline

week 2

week 4

week 8

week 12

week 13

CK [U/l]a

 mean ± SD

104.2 ± 50.29

195.1 ± 204.4

209.9 ± 272.0

272.1 ± 211.4**

234.5 ± 181.5*

128.1 ± 66.5†

0.002

 median

103.0

122.0

141.5

178.0

195.5

135.5

 range

33–192

34–817

39–1130

56–626

55–713

43–233

Mb [μg/l]a

 mean ± SD

76.5 ± 15.8

92.5 ± 33.3

90.5 ± 30.2

100.4 ± 32.7

93.5 ± 34.0

81.4 ± 24.4

0.080

 median

78.0

86.0

80.0

90.0

91.0

75.0

 range

42–102

52–182

42–166

73–190

62–187

48–136

  1. Statistically significant differences are marked in bold type and indicated by p < 0.05
  2. Abbreviations: CK Creatine kinase, Mb Myoglobin, WB-EMS Whole-body electromyostimulation
  3. aNormal values: CK < 190 U/l, Mb < 70 μg/l.
  4. bNonparametric repeated measures comparison over time (Friedman test) in the WB-EMS group (n = 14). CK values changed statistically significantly over time (p < 0.05) with significant differences of CK values at week 8 and 12 compared to baseline (Dunn’s multiple comparisons test; * p ≤ 0.05, ** p ≤ 0.01). One week after last WB-EMS session (week 13) CK values were significantly decreased compared to week 8 (†p ≤ 0.05). Data are presented as mean ± SD, median and range (minimum to maximum value)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us